|
Patent landscape, scope, and claims summary: |
United States Patent 11,040,113 Claims Analysis and US Patent Landscape: Scope, Expiration, Litigation Risk, and Generic Entry Barriers
United States Patent 11,040,113 (US 11,040,113) claim scope and US competitive risk hinge on what the patent actually covers (composition, formulation, method-of-use, device, or process), which active ingredient/product is implicated, and whether claims are tied to specific routes of manufacture or use. Without the patent text, claim set, and family members’ priority/filing data, a complete and accurate claims-by-claims analysis and landscape map cannot be produced.
What does US Patent 11,040,113 claim (independent and dependent claims)?
No complete claims analysis can be generated without the actual claim language of US 11,040,113, including:
- The preamble and claim type for each independent claim (composition, method, kit, use, process, or system).
- The key limitations that define scope (active ingredient identity, dosage form, particle size, excipients, process parameters, biomarkers, therapeutic indication, dosing schedule, patient population, device features, etc.).
- Dependency structure and which dependent claims narrow to specific embodiments (formulation variants, process steps, temperature ranges, catalyst systems, analytical thresholds, stability specs, packaging, or administration routes).
Which patent claims are likely the core infringement hooks for US 11,040,113?
No infringement-hook mapping can be performed without:
- Independent claim limitations and their likely “essential” features.
- Whether the patent uses functional language or “comprising” open transitions that broaden scope.
- Whether claims are drafted around structural features (hard to design around) or result/functional endpoints (often narrower in practice, but can be attacked on indefiniteness or lack of written description, depending on specification support).
How broad are the key claim limitations in US 11,040,113 (composition vs method vs process)?
A breadth assessment requires the precise terms used in the claims, including:
- Claim markers that control breadth: ranges, optional components, “at least” versus “about,” “substantially,” “effective amount,” and any comparator limitations.
- Whether the claims are tied to a specific formulation platform (e.g., polymer matrix, lipid nanoparticles, lyophilized cakes, sustained-release coatings).
- Whether the claims depend on process parameters that would limit read-across to other manufacturing routes.
When does US 11,040,113 expire, and what exclusivity could still block generics?
A defensible expiration timeline requires:
- Filing date, earliest priority date, and whether any terminal disclaimer is present.
- Whether any Patent Term Adjustment (PTA) or Patent Term Extension (PTE) exists.
- Whether the patent is listed in the FDA Orange Book (small-molecule drug products) or whether it relates to an approved biologic subject to BPCIA exclusivity.
- Whether exclusivity periods (NCE, 5-year, pediatric, 12-year/6-year, etc.) overlap independently of the patent term.
Is US 11,040,113 listed in the FDA Orange Book, and what products does it cover?
A correct Orange Book status check requires the actual drug product connection. This cannot be produced without:
- The Orange Book application number (NDA/BLA), proprietary name, active ingredient(s), and dosage form.
- Patent listing details: “drug substance” vs “drug product” vs “method of use,” plus listed expiration dates and submission type.
What patent estate surrounds US 11,040,113 (family members, continuations, continuations-in-part, and divisionals)?
A comprehensive landscape for one US patent requires:
- The patent family: all US applications in the family (including continuations and divisionals).
- Publication numbers and grant numbers.
- Priority chain and whether different family members cover distinct claim sets (formulation vs method vs process).
- Status of each family member: pending, granted, expired, revoked, or lapsed.
How many patents cover the same subject matter as US 11,040,113 in the US?
A “how many patents” metric requires:
- Claim-similarity clustering across co-owned and co-patented assets.
- A defined comparator set (same active ingredient/product concept vs same manufacturing platform vs same use/indication).
- A search strategy grounded in the claim terms, specification keywords, and assignee.
Which companies are potential freedom-to-operate (FTO) challengers to US 11,040,113?
A competitor risk map requires:
- The assignee and known licensees.
- The drug/product context (therapeutic area and market segment).
- Any known Paragraph IV filing activity, ANDA generic sponsors, or BLA biosimilar developers tied to the same product.
What Paragraph IV challenges exist that may involve US 11,040,113?
An accurate Paragraph IV analysis requires:
- The NDA and Orange Book listing tied to US 11,040,113.
- The Paragraph IV settlement notices (Hatch-Waxman) and litigation dockets referencing the patent.
- Whether US 11,040,113 is asserted as a “listed patent” in any ANDA litigation and whether it is asserted for infringement of a specific generic product.
What patent litigation affects US 11,040,113 (district court cases, PTAB challenges, or appeals)?
This requires:
- Court case captions, case numbers, asserted claims, and parties.
- Whether there have been IPR/CBM challenges at the PTAB, including institution decisions and final written decisions.
- Whether any claims were narrowed via amendment during prosecution or invalidated post-grant.
Are there PTAB IPR challenges to US 11,040,113 that constrain its claim scope?
A PTAB constraint analysis needs:
- Petitions and institution outcomes.
- Claim-by-claim survival.
- Final written decision results and any appeal status.
How strong is the patent estate for the technology claimed in US 11,040,113?
“Strength” requires measurable inputs:
- Claim breadth and structural defensibility.
- Validity attack surface: anticipation/obviousness risk, written description, enablement, indefiniteness, and obviousness-type double patenting.
- Prosecution history and whether claims were narrowed.
- Whether the estate contains multiple layers of fallback claims covering different embodiments.
What generic entry risks exist for the drug product linked to US 11,040,113?
A realistic generic risk scenario requires:
- The linked Orange Book product, including dosage form and whether method-of-use claims are listed.
- The claim type: product claims vs method-of-use vs process.
- Whether design-around exists (different formulation, different particle size, alternate excipient system, alternate dosing, different patient selection).
- Whether the generic would need a Paragraph IV certification that triggers litigation and potential 30-month stay.
How does US 11,040,113 compare with other patents in the same therapeutic space or formulation platform?
A comparative landscape requires:
- The closest prior patents asserted as blocking or freedom-to-operate references.
- Whether later patents in the same family broaden claims, tighten them, or switch from composition to method claims.
What formulation and dosage-form elements are protected by US 11,040,113?
This cannot be generated without the specification and claim language. A proper formulation mapping must identify:
- Dosage form: immediate-release, extended-release, orally disintegrating, injectable, topical, implant, inhalation, etc.
- Protected components: polymer matrices, surfactants, stabilizers, preservatives, buffers, solubilizers.
- Protected parameters: viscosity, pH, osmolality, stability under stress conditions, release profile, particle size distributions, and critical quality attributes.
What method-of-use limitations are protected by US 11,040,113 (indication, dosing, and patient population)?
A method-of-use analysis requires:
- Indication/endpoint language (biomarkers, severity stages, line of therapy).
- Dosing regimen specifics (mg, frequency, titration, duration).
- Patient selection criteria (genotype, prior therapy failure, comorbidities, contraindication exclusions).
- Whether claims are directed to treating a condition or using a composition in a particular regimen.
What manufacturing or process steps are protected by US 11,040,113?
A process claim landscape requires:
- Steps enumerated in claims (mixing order, temperatures, times, shear rates, milling, filtration, sterilization method, drying method).
- Whether steps are mandatory or optional.
- Whether the claims cover intermediates and whether those intermediates can be designed around.
Key Takeaways
No claims-level analysis, expiration determination, Orange Book status mapping, or litigation risk assessment for US 11,040,113 can be completed without the patent’s claim text, bibliographic data (priority and filing), assignee, and linked FDA product context.
FAQs
- Does US 11,040,113 cover a composition, method-of-use, or a manufacturing process?
- What is the earliest priority date for US 11,040,113 and how does that drive US expiration?
- Is US 11,040,113 listed as a method-of-use or drug product patent in the Orange Book?
- Have any IPR petitions challenged the validity of US 11,040,113 claims?
- Which generic sponsors or biosimilar developers face the highest infringement risk for the technology protected by US 11,040,113?
References
(No sources cited because the patent text and bibliographic links required for an accurate, complete landscape are not present.)
More… ↓
⤷ Start Trial
|
